COVID19 Update: All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are now available for routine office visits. VCS is keeping updated on current state and local guidance for the Covid vaccine rollout plan. FOR THE LATEST UP TO DATE INFORMATION, ALERTS, VACCINE INFORMATION AND CANCELLATIONS PLEASE CLICK HERE

Dr. Robert Reid of Virginia Cancer Specialists presents data on an important Study for Prostate Cancer

Virginia Cancer Specialists Practice Blog

February 07, 2018
Virginia Cancer Specialists » VCS Practice News » Genetics » VCS Practice News » Genetic Risk Assessment » Dr. Robert Reid of Virginia Cancer Specialists presents data on an important Study for Prostate Cancer

® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation

SALT LAKE CITY, Feb. 07, 2018 (GLOBE NEWSWIRE) —  Find out more here, read the full article.

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study of the Myriad myRisk® Hereditary Cancer test will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif.  The key finding is that more than 12 percent of men with prostate cancer had an inherited (i.e. hereditary) mutation in a cancer-causing gene.

Learn about Genetic Testing at Virginia Cancer Specialists Here